TY - JOUR
T1 - Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for epstein-barr-virus-driven disorders
AU - Martorelli, Debora
AU - Muraro, Elena
AU - Merlo, Anna
AU - Turrini, Riccardo
AU - Faè, Damiana Antonia
AU - Rosato, Antonio
AU - Dolcetti, Riccardo
PY - 2012
Y1 - 2012
N2 - The recent demonstration that immunotherapeutic approaches may be clinically effective for cancer patients has renewed the interest for this strategy of intervention. In particular, clinical trials using adoptive T-cell therapies disclosed encouraging results, particularly in the context of Epstein-Barr-virus- (EBV-) related tumors. Nevertheless, the rate of complete clinical responses is still limited, thus stimulating the development of more effective therapeutic protocols. Considering the relevance of innate immunity in controlling both infections and cancers, innovative immunotherapeutic approaches should take into account also this compartment to improve clinical efficacy. Evidence accumulated so far indicates that innate immunity effectors, particularly NK cells, can be exploited with therapeutic purposes and new targets have been recently identified. We herein review the complex interactions between EBV and innate immunity and summarize the therapeutic strategies involving both adaptive and innate immune system, in the light of a fruitful integration between these immunotherapeutic modalities for a better control of EBV-driven tumors.
AB - The recent demonstration that immunotherapeutic approaches may be clinically effective for cancer patients has renewed the interest for this strategy of intervention. In particular, clinical trials using adoptive T-cell therapies disclosed encouraging results, particularly in the context of Epstein-Barr-virus- (EBV-) related tumors. Nevertheless, the rate of complete clinical responses is still limited, thus stimulating the development of more effective therapeutic protocols. Considering the relevance of innate immunity in controlling both infections and cancers, innovative immunotherapeutic approaches should take into account also this compartment to improve clinical efficacy. Evidence accumulated so far indicates that innate immunity effectors, particularly NK cells, can be exploited with therapeutic purposes and new targets have been recently identified. We herein review the complex interactions between EBV and innate immunity and summarize the therapeutic strategies involving both adaptive and innate immune system, in the light of a fruitful integration between these immunotherapeutic modalities for a better control of EBV-driven tumors.
UR - http://www.scopus.com/inward/record.url?scp=84858196257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858196257&partnerID=8YFLogxK
U2 - 10.1155/2012/931952
DO - 10.1155/2012/931952
M3 - Article
C2 - 22319542
AN - SCOPUS:84858196257
VL - 2012
JO - Clinical and Developmental Immunology
JF - Clinical and Developmental Immunology
SN - 1740-2522
M1 - 931952
ER -